Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, McGuire V, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM.

Eur J Neurol. 2011 May;18(5):756-65. doi: 10.1111/j.1468-1331.2011.03353.x. Epub 2011 Jan 31.

2.

Human cytochrome P4501A2.

Landi MT, Sinha R, Lang NP, Kadlubar FF.

IARC Sci Publ. 1999;(148):173-95. Review.

PMID:
10493258
3.

Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Ross GW, Petrovitch H.

Drugs Aging. 2001;18(11):797-806. Review.

PMID:
11772120
4.

Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.

Schwarzschild MA, Chen JF, Ascherio A.

Neurology. 2002 Apr 23;58(8):1154-60. Review.

PMID:
11971080
5.

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF.

Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. Review.

PMID:
14663012
6.

Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.

Kalda A, Yu L, Oztas E, Chen JF.

J Neurol Sci. 2006 Oct 25;248(1-2):9-15. Epub 2006 Jun 27. Review.

PMID:
16806272
7.

Alcohol Consumption and Parkinson's Disease Risk: A Review of Recent Findings.

Bettiol SS, Rose TC, Hughes CJ, Smith LA.

J Parkinsons Dis. 2015;5(3):425-42. doi: 10.3233/JPD-150533. Review.

8.

Pathophysiological roles for purines: adenosine, caffeine and urate.

Morelli M, Carta AR, Kachroo A, Schwarzschild MA.

Prog Brain Res. 2010;183:183-208. doi: 10.1016/S0079-6123(10)83010-9. Review.

9.

The neuroprotective effects of caffeine in neurodegenerative diseases.

Kolahdouzan M, Hamadeh MJ.

CNS Neurosci Ther. 2017 Apr;23(4):272-290. doi: 10.1111/cns.12684. Review.

PMID:
28317317
10.

Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.

Chen X, Ghribi O, Geiger JD.

J Alzheimers Dis. 2010;20 Suppl 1:S127-41. doi: 10.3233/JAD-2010-1376. Review.

11.

Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption.

Coffee and Caffeine Genetics Consortium, Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N, Fischer K, Renstrom F, Ngwa JS, Huikari V, Cavadino A, Nolte IM, Teumer A, Yu K, Marques-Vidal P, Rawal R, Manichaikul A, Wojczynski MK, Vink JM, Zhao JH, Burlutsky G, Lahti J, Mikkilä V, Lemaitre RN, Eriksson J, Musani SK, Tanaka T, Geller F, Luan J, Hui J, Mägi R, Dimitriou M, Garcia ME, Ho WK, Wright MJ, Rose LM, Magnusson PK, Pedersen NL, Couper D, Oostra BA, Hofman A, Ikram MA, Tiemeier HW, Uitterlinden AG, van Rooij FJ, Barroso I, Johansson I, Xue L, Kaakinen M, Milani L, Power C, Snieder H, Stolk RP, Baumeister SE, Biffar R, Gu F, Bastardot F, Kutalik Z, Jacobs DR Jr, Forouhi NG, Mihailov E, Lind L, Lindgren C, Michaëlsson K, Morris A, Jensen M, Khaw KT, Luben RN, Wang JJ, Männistö S, Perälä MM, Kähönen M, Lehtimäki T, Viikari J, Mozaffarian D, Mukamal K, Psaty BM, Döring A, Heath AC, Montgomery GW, Dahmen N, Carithers T, Tucker KL, Ferrucci L, Boyd HA, Melbye M, Treur JL, Mellström D, Hottenga JJ, Prokopenko I, Tönjes A, Deloukas P, Kanoni S, Lorentzon M, Houston DK, Liu Y, Danesh J, Rasheed A, Mason MA, Zonderman AB, Franke L, Kristal BS; International Parkinson’s Disease Genomics Consortium (IPDGC); North American Brain Expression Consortium (NABEC); UK Brain Expression Consortium (UKBEC), Karjalainen J, Reed DR, Westra HJ, Evans MK, Saleheen D, Harris TB, Dedoussis G, Curhan G, Stumvoll M, Beilby J, Pasquale LR, Feenstra B, Bandinelli S, Ordovas JM, Chan AT, Peters U, Ohlsson C, Gieger C, Martin NG, Waldenberger M, Siscovick DS, Raitakari O, Eriksson JG, Mitchell P, Hunter DJ, Kraft P, Rimm EB, Boomsma DI, Borecki IB, Loos RJ, Wareham NJ, Vollenweider P, Caporaso N, Grabe HJ, Neuhouser ML, Wolffenbuttel BH, Hu FB, Hyppönen E, Järvelin MR, Cupples LA, Franks PW, Ridker PM, van Duijn CM, Heiss G, Metspalu A, North KE, Ingelsson E, Nettleton JA, van Dam RM, Chasman DI.

Mol Psychiatry. 2015 May;20(5):647-656. doi: 10.1038/mp.2014.107. Epub 2014 Oct 7. Review.

12.

Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases.

Madeira MH, Boia R, Ambrósio AF, Santiago AR.

Mediators Inflamm. 2017;2017:4761081. doi: 10.1155/2017/4761081. Epub 2017 Jan 31. Review.

13.

Coffee, Genetic Variants, and Parkinson's Disease: Gene-Environment Interactions.

Yamada-Fowler N, Söderkvist P.

J Caffeine Res. 2015 Mar 1;5(1):3-10. Review.

Supplemental Content

Support Center